Asiantuntijamme ovat kirjoittaneet, osallistuneet ja antaneet näkemystä satoihin julkaisuihin.
Cummins E, Asseburg C, et al. Cost-effectiveness of infliximab for the treatment of active and progressive psoriatic arthritis. Value Health 2011;14(1):15-23.
Peura P, Asseburg C, Turunen J, Purmonen T, Martikainen J. Epäsuora vertailu ja verkostometa-analyysit – uudet työkalut lääkkeiden suhteellisen tehon ja vaikuttavuuden arviointiin. (Indirect comparison and network meta-analyses – new tools for the assessment of evidence on the relative efficacy of drugs.) Aikakauskirja Duodecim 2011;127(9):900-10.
Blomster H, et al. Impaired nasal breathing may prevent the beneficial effect of weight loss in the treatment of OSA. Rhinology 2011;49:587-92. Collaborators: Soini E, Martikainen J.
Purmonen TT, Pänkäläinen E, Turunen JH, Asseburg C, Martikainen JA. Short-course adjuvant trastuzumab therapy in early stage breast cancer in Finland: Cost-effectiveness and value of information analysis based on the 5-year follow-up results of the FinHer Trial. Acta Oncol 2011;50(3):344-52.
Soini E. ESiOR laittaa numerot puhumaan. KunnallisSuomi 2010;(10):8.
Erntoft S, Asseburg C, et al. Vilken betydelse har hälsoekonomi vid prioriteringar? – Ett experiment bland beslutsfattare och en analys av faktiska prioriteringar. Linköping, Prioriteringscentrum 2010:3.
Martikainen J. Lääkehoitojen taloudellisen arvon arvioinnin perusperiaatteet. Onko lääke hintansa väärti? Lääkepäivät. Mar 19-20, 2010. Toim. Pirinen O, Aducate Reports and Books 1/2010: 78-79. Itä-Suomen yliopisto. Koulutus- ja kehittämispalvelu Aducate, Kuopio 2010. Podium.
Asseburg C. Experiences from The United Kingdom and Sweden in conducting pharmacoeconomic studies. Onko lääke hintansa väärti? Lääkepäivät. Mar 19-20, 2010. Toim. Pirinen O, Aducate Reports and Books 1/2010:80-81. Itä-Suomen yliopisto. Koulutus- ja kehittämispalvelu Aducate, Kuopio 2010. Podium.
Karttunen K, Karppi P, Hiltunen A, Vanhanen M, Välimäki T, Martikainen J, et al. Neuropsychiatric symptoms and quality of life in patients with very mild and mild Alzheimer’s disease. Int J Geriatr Psychiatry 2011;26(5):473-82.
Hallinen T, Soini E. The impact of the pharmaceutical pricing system on cost-effectiveness results: Finnish analysis. The Open Pharmacoeconomics & Health Economics Journal 2011;3:6-10.
Soini E, Martikainen J, et al. Treatment of follicular non-Hodgkin lymphoma with or without rituximab: Cost-effectiveness and value of information based on 5-year follow-up. Ann Oncol 2011;22(5):1189-97.
Ryynänen OP, Laitinen T, Soini E, et al. Bayesian methods for predicting treatment results. ECHE 2010. Podium.
Soini E, Hallinen T. Health economic study using survey data and modelling: Agomelatine, generic venlafaxine and placebo in the treatment of major depressive disorder. European Conference on Health Economics (ECHE) 2010.
Asseburg C, Ramsberg J, Peura P, Henriksson M, Purmonen T, Turunen J, Martikainen J. A Bayesian assessment of decision uncertainty in the choice between triptans for the treatment of migraine in Finland. International Society for Bayesian Analysis (ISBA) 2010 World Meeting on Bayesian Statistics.
Peura P, Purmonen T, Turunen J, Martikainen J. Tulosmuuttujan määrittämiseen liittyvä malliepävarmuus kustannusvaikuttavuusanalyyseissä. Podium. In: Klavus J (ed.) Terveystaloustiede 2010. Helsinki: THL, 74–7.
Soini E. Cost-effectiveness of modern anticoagulation treatment. Session: Who benefits from modern anticoagulation treatment – Practical guidelines. Kardiologian päivät. Oct 14, 2010.
Kokonaisuus ratkaisee kustannusvaikuttavuuden. BI News 2010; syksy:4. Haastateltu: Soini, E.
Soini E. Trabektediinin kustannusvaikuttavuus edenneen pehmytkudossarkooman hoidossa. Harvinaiset sairaudet -päivä. Oct 29, 2010. Finlandia-talo, Helsinki. Podium.
Asseburg C. Model uncertainty in cost-effectiveness analysis. Combining Epidemiology & Economics for Measurement of Cancer Costs. Villa Mondragone, Italy, September 23, 2010. Podium.
Soini E, Hallinen T, et al. Cost-utility and multinomial expected value of perfect information of sequenced treatment with biologics in moderate-to-severe rheumatoid arthritis: Analysis based on clinically meaningful responses. Value in Health 2010;13:A310.
Cummins E, Asseburg, C, et al. Cost-effectiveness of golimumab in psoriatic arthritis from the UK payer perspective. Value in Health 2010;13(7):A308.
Hallinen T, Soini E. The impact of Finnish pharmaceutical pricing scheme in cost-effectiveness analyses. Value in Health 2010;13(7):A249. Podium at the Annual ISPOR European Congress.
Soini E, Hallinen T, et al. Cost-effectiveness, value of information and budget impact of certolizumab pegol compared to subcutaneous tumor necrosis factor (TNF) inhibitors and methotrexate in the treatment of moderate-to-severe rheumatoid arthritis in Finland. Value Health 2010;13(7):A243. Podium at the Annual ISPOR European Congress.
Willis M, Asseburg C, et al. The economic impact of weight loss for patients with newly diagnosed type 2 diabetes mellitus (T2DM) in the US. Value in Health 2010;13(3):A59.
Soini E, Martikainen J, et al. Economic evaluation of lacosamide in the treatment of partial-onset epilepsy in Finland: Cost-effectiveness and budget impact modelling. ECHE 2010.
Soini E, Hallinen T, et al. Comprehensive health economic assessment of sequenced treatment with biologics in moderate-to-severe rheumatoid arthritis: Analysis based on ACR50 and ACR70 responses. Arthritis & Rheumatology 2010;62 Suppl 10:759. Poster at the Annual Scientific Meeting of American College of Rheumatology (ACR/ARHP 2010). ACR Notable Poster Nomination.
Hjalte F, Asseburg C, et al. Cost-effectiveness of a barrier-strengthening moisturizing cream as maintenance therapy vs. no treatment after an initial steroid course in patients with atopic dermatitis in Sweden – with model applications for Denmark, Norway and Finland. J Eur Acad Dermatol Venereol 2010;24(4):474-80.
Wailoo AJ, Goodacre S, Sampson F, Hernández Alava M, Asseburg C, et al. Primary angioplasty versus thrombolysis for acute ST-elevation myocardial infarction: an economic analysis of the National Infarct Angioplasty Project. Heart 2010;96(9):668-72.
Martikainen J, Nyblin K. Millainen on hyvä lääkkeen hoidollisen ja taloudellisen arvon arviointi? Dosis 2010;26:33-42.
Smout S, Asseburg C, et al. The functional response of a generalist predator. PLoS One 2010;5(5):e10761